Hypoglycemia (Hypo) is a common adverse effect of type 2 diabetes (T2D) therapy. Hypo has a negative impact on healthcare resources and quality of life (QoL) and can affect compliance and T2D control OBJECTIVES: To estimate the impact of Hypo on the QoL as well as its prevalence on T2D patients in Greece. METHODS: A cross-sectional epidemiological study was conducted in 6631 patients with T2DM. Hypo events with different treatment regimens, T2D control rates and QoL were assessed. Hypo episodes were defined as laboratory-confirmed (<70 mg/dl) symptomatic events. QoL was measured using the patient-administered ADDQoL-19 questionnaire. Diabetes control was defined as Hb1Ac ≤7%. RESULTS: The majority of the sample were male (55%) and overweight (59% had BMI 25-29.9). 20.4% of T2DM patients had a history of laboratory-confirmed hypoglycemia. In total, 59% had HbA1c >7%. The mean age was 60 and the mean T2D duration was 10 years. The mean QoL score of the total sample was -3.1± 1.9, the mean score of non-hypoglycemic patients was -3.05 ± 2.0 while the respective score of hypoglycemic patients was -3.26 ±1.8, (p≤0.005). Similar results were observed in the group of controlled patients and uncontrolled patients, who scored -2.73±1.7 and -3.33±1.9, respectively (p≤0.005). Comparable results were identified in the majority of the ADDQoL-19 instruments’ dimensions. According to the logistic regression analysis the majority of the ADDQoL-19 dimensions were significantly affected by hypoglycemia, as well as by high levels of HbA1c.  CONCLUSIONS: The study confirmed that the QoL of Greek T2D patients is negatively affected by hypoglycemic events and the level of the disease control. In T2D, treatment should attain good glycemic control without debilitating hypoglycemic episodes, which compromise patients’ QoL.